CHEK2 germline pathogenic variants have generally been associated with a moderate increased risk of breast cancer during life in BRCA1/2 negative patients [30], although an increased risk for syndromic familial non-medullary thyroid carcinomas has also been suggested [31]. Here, CHEK2 is linked to breast cancer.